Evaluation of Cisplatin-Loaded Polymeric Micelles and Hybrid Nanoparticles Containing Poly(Ethylene Oxide)-Block-Poly(Methacrylic Acid) on Tumor Delivery
- 1 Department of Drug Delivery Research, Hoshi University, Shinagawa, Japan
- 2 Department of Drug Delivery Research, Hoshi University, Shinagawa, Japan
- 3 Department of Physical Chemistry, Hoshi University, Shinagawa, Japan
- 4 Department of Drug Delivery Research, Hoshi University, Shinagawa, Japan
Abstract
Particulate carriers such as polymeric micelles (PMs) and liposomes have been investigated to increase drug accumulation in tumors and reduce distribution to healthy tissues. In this study, we prepared PM and hybrid nanoparticles (HNPs) with poly(ethylene oxide)-block-poly(methacrylic acid) (PEO-b-PMAA) for loading cisplatin, and evaluated cisplatin release, cytotoxicity, and biodistribution in mice. PM composed of PEO-b-PMAA and HNPs composed of egg phosphatidylcholine (EPC)/PEO-b-PMAA at molar ratios of 50/2.8 (HNP-P5) and 50/50 (HNP-P50), respectively, were prepared by a nanoprecipitation method. The sizes of PM, HNP-P5, and HNP-P50 after inclusion of cisplatin were approximately 200, 100, and 55 nm, respectively, and their entrapment efficiencies were approximately 44% - 66%. In the drug-release study, HNP-P5 and HNP-P50 showed reduced release of cisplatin compared with PM. Regarding the cytotoxic assay, HNP-P5 exhibited lower cytotoxicity for mouse Lewis lung carcinoma (LLC) and mouse colon carcinoma Colon 26 cells than PM and HNP-P50. In terms of biodistribution, PM could significantly improve blood circulation and tumor accumulation after intravenous injection into Colon 26 tumor-bearing mice compared with free cisplatin, but HNP-P5 and HNP-P50 did not. EPC in HNPs might be destabilized in the circulation, although it could reduce release of cisplatin in in vitro experiments. This study suggested that polymeric micelles composed of PEO-b-PMAA are a better carrier for cisplatin than hybrid nanoparticles composed of PEO-b-PMAA and EPC.
- Kelland, L. (2007) The Resurgence of Platinum-Based Cancer Chemotherapy. Nature Reviews Cancer, 7, 573-584. http://dx.doi.org/10.1038/nrc2167
- Homesley, H.D., Bundy, B.N., Hurteau, J.A. and Roth, L.M. (1999) Bleomycin, Etoposide, and Cisplatin Combination Therapy of Ovarian Granulosa Cell Tumors and Other Stromal Malignancies: A Gynecologic Oncology Group Study. Gynecologic Oncology, 72, 131-137. http://dx.doi.org/10.1006/gyno.1998.5304
- Ray-Coquard, I., Biron, P., Bachelot, T., Guastalla, J.P., Catimel, G., Merrouche, Y., Droz, J.P., Chauvin, F. and Blay, J.Y. (1998) Vinorelbine and Cisplatin (CIVIC Regimen) for the Treatment of Metastatic Breast Carcinoma after Failure of Anthracycline- and/or Paclitaxel-Containing Regimens. Cancer, 82, 134-140. http://dx.doi.org/10.1002/(SICI)1097-0142(19980101)82:1 3.0.CO;2-3
- Miller, R.P., Tadagavadi, R.K., Ramesh, G. and Reeves, W.B. (2010) Mechanisms of Cisplatin Nephrotoxicity. Toxins (Basel), 2, 2490-2518. http://dx.doi.org/10.3390/toxins2112490
- Quasthoff, S. and Hartung, H.P. (2002) Chemotherapy-Induced Peripheral Neuropathy. Journal of Neurology, 249, 9-17. http://dx.doi.org/10.1007/PL00007853
- Kurihara, N., Kubota, T., Hoshiya, Y., Otani, Y., Ando, N., Kumai, K. and Kitajima, M. (1996) Pharmacokinetics of Cis-Diamminedichloroplatinum (II) Given as Low-Dose and High-Dose Infusions. Journal of Surgical Oncology, 62, 135-138. http://dx.doi.org/10.1002/(SICI)1096-9098(199606)62:2 3.0.CO;2-7
- Simon, T., Hero, B., Dupuis, W., Selle, B. and Berthold, F. (2002) The Incidence of Hearing Impairment after Successful Treatment of Neuroblastoma. Klinische Padiatrie, 214, 149-152. http://dx.doi.org/10.1055/s-2002-33179
- El-Sayyad, H., Ismail, M.F., Shalaby, F.M., Abou-El-Magd, R.F., Gaur, R.L., Fernando, A., Raj, M.H. and Ouhtit, A. (2009) Histopathological Effects of Cisplatin, Doxorubicin and 5-Flurouracil (5-FU) on the Liver of Male Albino Rats. International Journal of Biological Sciences, 5, 466-473. http://dx.doi.org/10.7150/ijbs.5.466
- Newman, M.S., Colbern, G.T., Working, P.K., Engbers, C. and Amantea, M.A. (1999) Comparative Pharmacokinetics, Tissue Distribution, and Therapeutic Effectiveness of Cisplatin Encapsulated in Long-Circulating, Pegylated Liposomes (SPI-077) in Tumor-Bearing Mice. Cancer Chemotherapy and Pharmacology, 43, 1-7. http://dx.doi.org/10.1007/s002800050855
- Slingerland, M., Guchelaar, H.J. and Gelderblom, H. (2012) Liposomal Drug Formulations in Cancer Therapy: 15 Years along the Road. Drug Discovery Today, 17, 160-166. http://dx.doi.org/10.1016/j.drudis.2011.09.015